BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager

Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...

August 26, 2025 | News

Asia Bio Innovation Summit 2025 Highlights ADC and CGT as Dual Engines of Biopharma Innovation

Asia Bio Innovation Summit 2025 is one of the premier industry-focused events in Asia and focus on the hottest topics of ADC and CGT. Asia B...

August 25, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Akeso Doses First Patient in Phase III COMPASSION-33 Trial of Cadonilimab for Perioperative Gastric Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-31...

August 21, 2025 | News

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Mabwell Doses First U.S. Patient in Global Trial of Novel Nectin-4 ADC for Hard-to-Treat Triple-Negative Breast Cancer

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced the first patient dosing in the U.S. for a clinical stud...

August 13, 2025 | News

RemeGen Secures FDA Clearance for Phase II Trials of Innovative Bispecific Antibody RC148 in Advanced Solid Tumors

RemeGen Co., announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bisp...

August 11, 2025 | News

Mabwell’s CDH17-Targeting ADC 7MW4911 Receives IND Clearance in China and U.S.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug ...

August 04, 2025 | News

Alphamab Oncology’s Bispecific ADC JSKN022 Clears IND Review in China

Alphamab Oncology announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug...

August 04, 2025 | News

Alphamab Oncology’s HER2-Targeting ADC JSKN003 Secures FDA Orphan Drug Designation for Gastric and GEJ Cancers

Alphamab Oncology announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Foo...

July 29, 2025 | News

Biocytogen Expands Preclinical Capabilities Across Asia and the U.S. with Over 1,000 Humanized Mouse Models

Biocytogen (HKEX: 02315), an international biotechnology company that drives new drug development with innovative technologies, announced that its pr...

July 29, 2025 | News

China’s DualityBio Secures FDA Fast Track for Next-Gen HER3 ADC DB-1310 in Advanced Lung Cancer

DualityBio announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting a...

July 23, 2025 | News

BioMed X and Servier Launch Europe’s First XSeed Labs at Paris-Saclay to Accelerate AI-Driven Bispecific Antibody Design

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced the launch of a new initiative with Se...

July 10, 2025 | News

InnoCare Pharma Receives IND Approval in China for Novel B7-H3 Targeted ADC ICP-B794

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the approval of the Inves...

July 07, 2025 | News

Stay Connected